IradimedIRMD.OValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Richly Valued” zone.
As of Oct 16, 2026, Iradimed (IRMD.O) trades at a P/E of 49.00x, P/B of 11.10x, P/S of 13.10x, and a dividend yield of 0.68%.
Longitudinal percentile comparison: P/E sits at the 63rd percentile over the trailing 10Y window (vs. 77th percentile over 3Y); P/B sits at the 93rd percentile over the trailing 10Y window (vs. 76th percentile over 3Y); P/S sits at the 90th percentile over the trailing 10Y window (vs. 77th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 82nd percentile within its industry and the 84th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.91%, ranking at the 56th percentile over the trailing 20Y window.
Notably, P/E and P/B aren't telling quite the same story, 29.9 points apart — worth checking the full percentile matrix on this page for the complete picture. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Of the 0.91% total shareholder yield, 0.68% is paid out as dividends and roughly 0.23% is implied to come from buybacks — both channels are meaningfully in play. Iradimed operates in the Manufacturing sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: NASDAQ: IRMD · IRMD
Want the full picture on whether Iradimed (IRMD.O) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 49.00 | ||||||
| P/B (MRQ) | 11.10 | ||||||
| P/S (TTM) | 13.10 | ||||||
| Dividend Yield | 0.68% | ||||||
| Buyback + Div Yield | 0.91% |